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SUMMARY
Uveal melanoma (UM), the most common ocular ma-
lignancy, is characterized by GNAQ/11 mutations.
Hippo/YAP and Ras/mitogen-activated protein ki-
nase (MAPK) emerge as two important signaling
pathways downstream of G protein alpha subunits
of the Q class (GaQ/11)-mediated transformation,
although whether and how they contribute to UM
genesis in vivo remain unclear. Here, we adapt an ad-
eno-associated virus (AAV)-based ocular injection
method to directly deliver Cre recombinase into the
mouse uveal tract and demonstrate that Lats1/2 ki-
nases suppress UM formation specifically in uveal
melanocytes. We find that genetic activation of
YAP, but not Kras, is sufficient to initiate UM. We
show that YAP/TAZ activation induced by Lats1/2
deletion cooperates with Kras to promote UM pro-
gression via downstream transcriptional reinforce-
ment. Furthermore, dual inhibition of YAP/TAZ and
Ras/MAPK synergizes to suppress oncogenic
growth of human UM cells. Our data highlight the
functional significance of Lats-YAP/TAZ in UM initia-
tion and progression in vivo and suggest combina-
tion inhibition of YAP/TAZ and Ras/MAPK as a new
therapeutic strategy for UM.
INTRODUCTION
Uveal melanoma (UM), the most common primary intraocular
malignancy in adults, arises from the melanocytes of the uveal
tract, which consists of the choroid, ciliary body, and iris (Singh
et al., 2005). Unlike cutaneous melanoma, UM is genetically
characterized by distinct mutations in GANQ and GNA11.
More than 80% of human UMs harbor activating mutations in
GNAQ or GNA11, which encode the heterotrimeric G protein
alpha subunits of the Q class (Gaq/11) (Van Raamsdonk et al.,
2009, 2010). The highly conserved glutamine 209 (Q209) or argi-
nine 183 (R183) mutations of GNAQ and GNA11 render the gua-
nosine triphosphatase (GTPase) of these proteins defective and
lead to constitutive activation of downstream pathways in UM
cells (Van Raamsdonk et al., 2009, 2010).
Ras/mitogen-activated protein kinase (MAPK) and Hippo/YAP
are two signaling pathways implicated downstream of GNAQ/11
during UM pathogenesis (Chen et al., 2014, 2017; Feng et al.,
2014; Moore et al., 2018; Van Raamsdonk et al., 2009; Yu
et al., 2014). In UM cells, activated Gaq/11 proteins are thought
to interact with their direct downstream effector, PLCb, resulting
in activation of protein kinase C (PKC) and further downstream,
in activation of Ras/MAPK signaling (Hubbard and Hepler,
2006). A recent report identifies PKCd/ε as the relevant PKC iso-
forms in UM (Chen et al., 2017), which provides a molecular link
on how PKC signaling relays to MAPK activation. In human UM
cells, PKC kinases phosphorylate and activate the Ras guanine
nucleotide exchange factors leading to activation of the Ras-
mitogen-activated protein kinase kinase-extracellular signal-
regulated kinase (MEK-ERK) signal cascade (Chen et al., 2017;
Moore et al., 2018). Despite the evidence of its functional impor-
tance, the ineffectiveness of targeting the MAPK pathway in UM
clinical trials (Carvajal et al., 2014; Komatsubara et al., 2016) sug-
gests the involvement of additional oncogenic pathways in
GNAQ/11-mutated UM cells.
Hippo/YAP signaling, originally identified in Drosophila as an
organ size control pathway, recently emerged as another key
pathway in UM tumorigenesis (Feng et al., 2014; Yu et al.,
2014). In the mammalian Hippo pathway, activation of the core
kinase cascade, which comprises the Mst1/2 and Lats1/2 ki-
nases, leads to phosphorylation, cytosolic retention, and degra-
dation of the transcriptional coactivators, YAP and TAZ. Upon
Hippo pathway inactivation, YAP and TAZ translocate into the
nucleus and interact with the Tead family of transcription factors,
thereby inducing downstream gene transcription (Halder and
Camargo, 2013; Pan, 2010; Yu et al., 2015; Zanconato et al.,
2016). Mis-regulation of the Hippo pathway has been implicated
in a variety of human cancers, including UM (Feng et al., 2014;
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Halder and Camargo, 2013; Pan, 2010; Yu et al., 2014, 2015;
Zanconato et al., 2016). A prior study showed strong regulation
of the Hippo pathway by G protein-coupled receptors (GPCRs)
through interaction with different G proteins, including Gaq/11,
the oncogenic drivers of UM (Yu et al., 2012). Two subsequent
studies reported the functional role of YAP in UM cells carrying
GNAQ/11 mutations (Feng et al., 2014; Yu et al., 2014).
Although YAP and Ras/MAPK are potentially critical for UM
genesis, it is still not clear whether their activation is able to drive
UM formation in vivo and how they functionally interact during
UM initiation and progression. Two recent studies generated
mouse models of UM by crossing the conditional mice carrying
the mutated GNAQ or GNA11 alleles in the Rosa26 locus to
two different mouse melanocyte Cre lines (Huang et al., 2015;
Moore et al., 2018). However, the broad Cre expression in the
melanocytes or melanocyte-like cells outside the eye, including
organs such as skin, CNS, lung, and inner ear, leads to early
lethality and complicates UM phenotypic analysis (Huang
et al., 2015; Moore et al., 2018). Here, we adapted an adeno-
associated virus (AAV)-based ocular injection method to allow
specific induction of Cre recombination in uveal melanocytes
and used this platform to manipulate Hippo/YAP and Ras/
MAPK signaling directly in mouse uveal tract. Our data revealed
a distinct role of Lats1/2-YAP/TAZ in UM initiation and progres-
sion, and suggest a transcriptional reinforcement mechanism
underlying the functional interplay between Hippo/YAP and
Ras/MAPK during UM development.
RESULTS
A Robust UM Mouse Model via AAV-Cre Uveal Tract
Delivery
In order to examine the role of Hippo signaling in UM genesis
in vivo, we adapted an AAV-based eye injection method (Venka-
tesh et al., 2013) for local delivery of AAV5-CMV-Cre viral vector
directly into the choroid region of the mouse uveal tract (Fig-
ure 1A). We then used this uveal tract injection method to deliver
Cre recombinases into adult mice carrying the floxed alleles for
both Lats1 and Lats2 genes, Lats1fl/fl;Lats2fl/fl (Yi et al., 2016),
or together with the reporter R26mT/mG allele (Muzumdar et al.,
Figure 1. A Mouse Model of UM via AAV-Based Cre Delivery Directly into the Uveal Tract
(A) Illustration of AAV-based delivery of Cre recombinases into the choroid region of a mouse uveal tract.
(B–G) UM genesis in Lats1fl/fl;Lats2fl/flmice following AAV5-CMV-Cre injection. Eye dissected from control mice (B), and UM isolated from Lats1fl/fl;Lats2fl/flmice
6 months after Cre injection (C).
(D–G) Representative histological images of wild-type eye (D) and UMs detected 3 months (E) and 6 months (F and G) after Cre injection.
(H) GFP expression in UM derived from AAV-Cre-injected Lats1fl/fl;Lats2fl/fl;R26mT/mG mice.
(I–K) Representative IHC images of (I) Melanoma cocktail, (J) Ki67, and (K) YAP in UM derived from AAV-Cre-injected Lats1fl/fl;Lats2fl/fl;R26mT/mG mice.
(L) Immunoblot analysis of protein expression of Lats2, YAP, phospho-YAP (p-YAP), and GAPDH in control and UM tissues using the antibodies against Lats2,
YAP, phospho-YAP (Ser127), and GAPDH.
(M and N) qPCR analysis of mRNA expression of Lats1, CTGF, Cyr61, and ANKRD1 in control and UM tissues.
Data are mean ± SD. **p% 0.01.
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2007) that drives the expression of membrane-bound GFP pro-
teins upon Cre recombination. We found that deletion of the
core Hippo kinases Lats1/2 through AAV-CMV-Cre injection effi-
ciently induced tumor formation. Within 2 months following
ocular Cre delivery, the majority of the mice exhibited bulging
eyes, and at 6months after Cre injection, most of themice devel-
oped eye tumors (Figures 1B–1G and 3A). Tumors developed in
themice carrying theR26mT/mG reporter allele wereGFP-positive
(Figure 1H), suggesting that they originated from the cells that
underwent Cre recombination. Tumor cells also stained posi-
tively for the melanoma antibody cocktail Melan A/Mart1-
HMB45 (Figure 1I), indicating that the tumors are UM in nature
and arise from themelanocytes. In addition, these highly prolifer-
ative Lats1/2-deleted tumor cells exhibited nuclear YAP staining,
downregulation of YAP phosphorylation, and upregulation of
YAP target genes, includingCTGF,Cyr61, and ANKRD1 (Figures
1J–1N). These data suggest that Hippo pathway inactivation by
Lats1/2 deletion drives UM formation, and that the AAV-based
eye local injection is an effective method to induce Cre recombi-
nation in the mouse uveal tract that can be used for UM tumor
modeling.
Lats1/2 Kinases Specifically Suppress UM Formation in
Mouse Uveal Melanocytes
To achieve specific deletion of Lats1/2 kinases in uveal melano-
cytes, we generated an AAV expression vector that drives the
expression of the nuclear GFP-Cre fusion protein under the
control of a 1.7-kbmouse tyrosinase-related protein 2 (Trp2) pro-
moter (Figure 2A). Trp2, an enzyme involved in an intermediate
step of melanin synthesis, is expressed in the adult uveal mela-
nocytes (Li et al., 2006), and the 1.7-kb mouse Trp2 promoter
has been shown to be able to direct transgene expression
(Zhao and Overbeek, 1999). Following AAV5-Trp2-GFPCre in-
jection, we detected sporadic expression of GFP-Cre within
the uveal tract, and the nuclear GFP signals were colocalized
with the melanocytes expressing Melan A (Figures 2B–2D),
Figure 2. Lats1/2 Kinases Suppress UM Formation Specifically in Uveal Melanocytes
(A) Diagram of the new Trp2-GFPCre allele. In Trp2-GFPCre, expression of the nuclear GFP-Cre fusion protein is under the control of a 1.7-kb mouse tyrosinase-
related protein 2 (Trp2) promoter.
(B–D) Sporadic nuclear GFP-Cre expression in uveal tract co-localizes with Melan A-expressing melanocytes in AAV5-Trp2-GFP-Cre-injected control mice.
Expression of Melan A is detected by immunofluorescence using an anti-Melan A/HMB45 antibody.
(E and F) UM developed in AAV5-Trp2-GFPCre-injected Lats1fl/fl;Lats2fl/fl;R26mT/mG mice does not express RPE65. GFP expression in tumors is mutually
exclusive from the RPE layer expressing the RPE65 marker. Note that GFP signals detected in tumor cells were generated from both GFP-Cre and membrane-
tethered GFP expression from the R26mT/mG allele after Cre recombination. Immunofluorescence against RPE65 is performed using an anti-RPE65 antibody in
both control (E) and AAV5-Trp2-GFPCre-injected Lats1fl/fl;Lats2fl/fl;R26mT/mG (F) mice.
(G–N) Representative IHC images of YAP/TAZ, Ki67, RPE65, and Melan A/HMB45 in control uveal tracts (G, I, K, and M) or UMs generated from AAV5-Trp2-
GFPCre-injected mice (H, J, L, and N).
See also Figure S1.
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confirming the specificity of Trp2-GFPCre expression in uveal
melanocytes. Likewhatwe observed in AAV5-CMV-Cre-injected
mice (Figure 1), we found that most of the Lats1/2 conditional
mice following AAV5-TRP2-GFPCre uveal tract injection devel-
oped UMs (Figures 2 and 5A). We showed that the GFP-positive
tumor cells carrying the R26mT/mG reporter allele were stained
negatively for RPE65 (Figures 2E and 2F), a specific marker for
the retinal pigmented epithelium (RPE). In addition, our immuno-
histochemistry (IHC) analysis showed that the Melan A-positive,
RPE65-negative tumor cells exhibited strong YAP/TAZ nuclear
staining (Figures 2G–2N). Interestingly, our data also revealed
that the cells in the RPE layer showed much higher nuclear
YAP/TAZ levels than the cells in the adjacent choroid region of
control animals (Figure 2G), suggesting that Hippo signaling
and Lats1/2 kinases normally function to suppress YAP/TAZ ac-
tivity in wild-type uveal melanocytes, and Lats1/2 removal in the
melanocytes leads to YAP/TAZ activation, thereby inducing
oncogenic transformation and subsequent UM formation.
YAP/TAZ Are Required and Sufficient for UM Initiation
Next,weset out to testwhetherYAP/TAZ isgenetically required for
UM formation induced by Lats1/2 deletion. We crossed the YAP
and TAZ conditional alleles, YAPfl and TAZfl (Xin et al., 2011,
2013), into the mice carrying Lats1/2 conditional alleles in order
to delete all four proteins simultaneously. We found that the mice
carrying the YAP/TAZ conditional alleles failed to develop UM up
to 8 months after Cre delivery (Figure 3A). Consistent with the re-
ported role of YAP/TAZ in mediating Lats1/2 function, YAP/TAZ
deletion abolished upregulation of downstream target gene
transcription inducedbyLats1/2deletion (FigureS1), and theuveal
tract appeared phenotypically normal in the mice carrying Lats1/2
and YAP/TAZ conditional alleles after Cre injection (Figure S1).
These data suggest that YAP/TAZ function is critical for UMdevel-
opment following Lats1/2 inactivation in uveal melanocytes.
To examine whether YAP activation alone is able to drive UM
formation, we utilized a Rosa26 conditional allele we recently
generated, R26YAP5SA, which allows Cre-mediated expression
of a constitutively active form of YAP, YAP5SA (Cotton et al.,
2017). YAP5SA has five canonical LATS phosphorylation sites
mutated from serine to alanine to prevent Hippo/Lats-mediated
inhibition and degradation (Zhao et al., 2007). The R26YAP5SA
allele also has a nuclear localization signal (NLS) and FLAG tag
at its N terminus and an IRES-nuclear LacZ tag at its C terminus
(Figure 3B). Consistent with the results in Cre-injected Lats1/2
conditional mice, most of the R26YAP5SA mice developed UMs
following Cre injection (Figures 3A and 3C). The YAP5SA trans-
gene expression in tumor cells was confirmed by western blot
using an anti-FLAG antibody (Figure 3D), as well as by the pos-
itive LacZ staining in tumor cells (Figure 3E). We found that the
tumor, but not the adjacent sclera tissue, expressed Melan A
(Figure 3F), and immunofluorescence staining showed YAP nu-
clear expression in Melan A-expressing tumor cells (Figure 3G).
Furthermore, we showed the elevated expression of the YAP
target genes, CTGF, Cyr61, and ANKRD1, in the tumors
Figure 3. YAP Activation Alone Is Sufficient to Drive UM Formation
(A) Tumor incidence in AAV5-CMV-Cre-injected mice with various genotypes.
(B) Schematic diagram of the R26YAP5SA allele.
(C) Histological images of UM developed in AAV5-CMV-GFPCre-injected R26YAP5SA mice.
(D) Immunoblot analysis of the expression of FLAG-tagged YAP5SA protein in tumors using an anti-FLAG antibody.
(E) LacZ staining shows YAP5SA transgene expression within tumor (UM), but not adjacent sclera tissue.
(F) IHC staining of Melan A in UM from AAV5-CMV-GFPCre-injected R26YAP5SA mice, using a Melanoma antibody cocktail.
(G) Immunofluorescence staining of Melan A and YAP showing nuclear YAP expression in Melan A-expressing tumor cells.
(H) qPCR analysis of mRNA levels of the YAP target genes, CTGF, Cyr61, and ANKRD1, in control tissue and YAP5SA-expressing UM.
Data are mean ± SD. **p% 0.01. See also Figure S2.
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Figure 4. YAP/Tead Promote Ras/MAPK Activation via Downstream Transcription
(A) Functional clustering of significantly upregulated genes in UM cells from Lats1/2 knockout (KO) mice.
(B) Representative IHC images of phosphorylated ERK1/2 (pERK1/2) in normal mouse uveal tract and UM from AAV5-Trp2-GFPCre-injected Lats1fl/fl;Lats2fl/fl
mice.
(C and D) Immunoblot analysis of protein levels of phospho-MEK1/2 (pMEK1/2), MEK1/2, phospho-ERK1/2 (pERK1/2), and ERK1/2 in control or UM tissues.
(E) qPCR analysis of mRNA levels of Pkrdc, Nras, Rras2, and RasGRP1 in control and UM tissues.
(F) Tead4 occupancy in the promoter regions of the CTGF, Cyr61, ANKRD1, Nras, Rras2, Prkcd, RasGRP1, and GAPDH (Control) genes in UM. Tead4
ChIP-qPCR analysis was performed in isolated mouse UM cells, and enrichment of Tead4 was calculated based upon qPCR relative to immunoglobulin G (IgG)
control.
(legend continued on next page)
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developed in the R26YAP5SA mice following AAV5-CMV-Cre in-
jection (Figure 3H). Taken together, these genetic data suggest
that activation of YAP/TAZ is likely necessary and sufficient for
UM induction in the uveal tract.
YAP/Tead Promote Ras/MAPK Activation via
Downstream Transcription
To explore the downstream mechanism underlying YAP/TAZ
during UM genesis, RNA-sequencing (RNA-seq) analysis was
performed to profile the transcriptome of UMs from our mouse
models (Table S1). Functional clustering analysis of the signifi-
cantly upregulated genes identified the MAPK cascade as the
second-highest ranked functional cluster, right behind the top-
ranked ‘‘G1/S transition of mitotic cell cycle’’ (Figure 4A), sug-
gesting a possible activation of the MAPK pathway in UM
induced by YAP activation. Consistent with this notion, the IHC
analysis identified the upregulation of phosphorylated ERK levels
in UM, in comparison with the control uveal tract (Figure 4B).
Western blot analysis also showed the increased phosphoryla-
tion of both MEK1/2 and ERK1/2 kinases (Figures 4C and 4D),
further confirming the activation of the Ras/MAPK cascade.
Among the genes associated with the Ras/MAPK signaling
cascade, we found that transcription of Prkcd, Rras2, NRas, and
RasGRP1was significantly upregulated inUMcells (Figure 4E; Ta-
ble S1). PKC isoform d (PKCd), which is encoded by the Prkcd
gene, was recently identified as a key signaling component linking
Gaq activation to Ras/MAPK activation in UM (Chen et al., 2017).
Nras, Rras2 (TC21), and RasGRP1 (a Ras-specific guanine nucle-
otide exchange factor) have been shown to activate MAPK in
different cellular settings (Cox and Der, 2010; Golec et al., 2016;
Graham et al., 1994; Larive et al., 2012). One of the Ras guanine
nucleotide exchange factors, RasGRP3, was recently reported
to play functional roles in Ras/MAPK activation in UM cells (Chen
et al., 2017; Moore et al., 2018). To further examine whether these
genes are possible downstream targets of the YAP/Tead tran-
scriptional complex,we intersected our datawith the TEAD4chro-
matin immunoprecipitation-sequencing (ChIP-seq) datasets avail-
able at the ENCODE project (https://www.encodeproject.org/)
and found Tead4 occupancy in the promoter or enhancer regions
of the humanRRAS2,NRAS, andPRKCD genes (Encode project),
suggesting that they are potential direct targets of Tead. Thus, we
performed Tead4 ChIP-qPCR in mouse UM cells with Lats1/2
deletion and found that, in addition to the known YAP/Tead direct
targets CTGF, Cyr61, and Ankrd1, Tead4 also occupied the pro-
moter regions of Rras2 and Nras in mouse UM cells (Figure 4E).
Although we did not detect significant enrichment of Tead4 occu-
pancy in thepromoter regionsofPrkcdandRasGRP1 (Figure4F), it
remains possible that they are directly regulated by YAP/Tead
through distal enhancers, as shown in the PRKCD locus in human
embryonic stem cells (ESCs) (Encode project).
To further examine YAP/TAZ regulation of Ras/MAPK
signaling in UM cells, we generated a lentiviral-based Tead4
repressor construct, DN-TEAD4. DN-TEAD4 lacks the N-termi-
nal DNA binding domain but retains the entire YAP/TAZ binding
domain that allows its interaction with endogenous YAP/TAZ to
block downstream transcriptional activation (Figure S3A). Similar
truncated repressor constructs of Tead2 and Sd (Drosophila
Tead) have been reported before (Chow et al., 2004; Liu-Chitten-
den et al., 2012). We demonstrated that DN-TEAD4 could effec-
tively inhibit both YAP- and TAZ-induced downstream gene
transcription, measured by the activity of a Tead binding site-
driven luciferase reporter (8XGIITC-Luc) (Figure S3B). More
importantly, DN-TEAD4 expression by lentiviral infection was
able to block endogenous transcription of the YAP/TAZ target
genes, CTGF, CYR61, and ANKRD1, in human 92-1 UM cells
(Figure 4G). 92-1 cells are a human UM cell line that carries the
characteristic GaqQL mutation and was previously shown to
be sensitive to YAP inhibition (Yu et al., 2014). In agreement
with our data frommouse UMswith Lats1/2 deletion or YAP acti-
vation, we found that Tead inhibition by DN-TEAD4 in human
92-1 cells also decreased RRAS2, NRAS, and PRKCD gene
transcription (Figure 4G). Western blot analysis showed downre-
gulation of Ras/MAPK activity in 92-1 cells by DN-TEAD4, as evi-
denced by decreased phosphorylation of both MEK1/2 and
ERK1/2 kinases (Figure 4H). Together, our data inmouse and hu-
man UM cells suggest that YAP/TAZ activation regulates MAPK
signaling by promoting transcription of a subset of downstream
targets associated with the Ras/MAPK cascade.
Kras Activation Promotes UM Progression In Vivo
To test whether Ras activation in the mouse uveal tract can
induce UM in vivo, we utilized the well-characterized KrasG12D
knockin allele, LSL-KrasG12D, which enables Cre-dependent
expression of activated Kras at the endogenous Kras locus
(Jackson et al., 2001). We found that, unlike Lats1/2 deletion or
YAP activation, Kras activation alone in uveal melanocytes was
not sufficient to driveUM formation after Cre injection (Figure 5A).
However, the combination of Lats1/2 deletion and Kras activa-
tion significantly accelerated tumor progression, measured by
tumor sizes and overall survival time of Cre-injected mice (Fig-
ures 5B–5E). After Cre injection, most of the mice carrying both
LSL-KrasG12D and Lats1/2 conditional alleles died within
4 months because of exuberant UM growth and deteriorated
health (Figure 5E). Not surprisingly, the tumors with Kras activa-
tion and Lats1/2 removal were more proliferative, as seen by
phospho-Histone H3 (pH3) IHC (Figure 5F), and exhibited higher
phospho-ERK1/2 levels than the tumors with only Lats1/2
removal, measured by both IHC and western blot analysis (Fig-
ures 5F and 5G). These data suggest that genetic Kras activation
alone is not sufficient to induce UM initiation; rather, it promotes
UM progression in conjunction with YAP/TAZ activation.
AP1 Transcriptional Upregulation in UMs with Kras
Activation
After comparing the tumors with Lats1/2 deletion with those with
Lats1/2 deletion and Kras activation, we noticed that the tumors
(G) qPCR analysis of mRNA levels of CTGF, CYR61, ANKRD1, PKRCD, NRAS, RRAS2, RASGRP1, and RASGRP3 in 92-1 UM cells with and without DN-TEAD4
expression.
(H) Immunoblot analysis of DN-TEAD4 (myc tag), GAPDH, pMEK1/2, MEK1/2, pERK1/2, and ERK1/2 in 92-1 UM cells with and without DN-TEAD4 expression.
Data are mean ± SD. *p% 0.05, **p% 0.01. See also Figure S3 and Table S1.
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Figure 5. Lats1/2 Deletion Synergizes with Kras Activation to Promote UM Progression
(A) Tumor incidence in AAV5-Trp2-GFPCre-injected mice with various genotypes.
(B–E) UM formation inAAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl andAAV-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl;LSL-KrasG12Dmice. H&E-stained sections of representative
tumors from each group are shown (B and C).
(D) The tumor areas from five injected mice 4 months after Cre recombination were quantified.
(E) Average survival time of the mice with different genotypes after Cre injection.
(F) Representative IHC images of phospho-Histone H3 (pH3) and phospho-ERK1/2 (pERK1/2) in UMs derived from AAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl and
AAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl;LSL-KrasG12D mice.
(legend continued on next page)
3206 Cell Reports 29, 3200–3211, December 3, 2019
with both YAP/TAZ and Kras activation exhibited significantly
higher mRNA levels of the YAP/Tead target genes, CTGF,
Cyr61, and ANKRD1 (Figure 5H). It raised an intriguing possibility
that Ras/MAPK activation might in turn promote YAP/Tead-
mediated transcriptional output in UM.
To test this hypothesis, we first looked at YAP, TAZ, and Tead
expression in mouse UM tumors with Lats1/2 deletion or Kras
activation and did not detect significant change in their mRNA
or protein levels, measured by qPCR or western blot analysis
(Figures 5G, 5H, and S4B). Additionally, there was no change
of YAP intracellular localization, because it remained in the nuclei
(Figure S4A). To further understand the underlyingmechanism of
the increased transcriptional output of YAP/Tead, we focused on
the activator protein 1 (AP1) factors. We and others recently re-
ported the widespread AP1-Tead co-occupancy at the promoter
or enhancer regions in the majority of the YAP/Tead target genes
(Liu et al., 2016; Zanconato et al., 2015). We demonstrated that
AP1-Tead cooperation acts as a major regulatory mechanism
to coordinate downstream gene expression in various cancer
cells (Liu et al., 2016; Zanconato et al., 2015). Thus, we examined
AP1 expression and found that both mRNA and protein expres-
sion of several AP1 factors, including c-Jun, JunB, Fos, FosL1,
and FosL2, were significantly upregulated in UMs with both
Kras activation and Lats1/2 removal (Figures 6A and 6B).
Furthermore, we performed c-Jun ChIP-qPCR on the promoter
regions of the YAP/Tead downstream genes, including CTGF,
Cyr61, ANKRD1, Myc, and CyclinD1, and found that there was
significant enrichment of c-Jun occupancy in their promoter re-
gions (Figure 6C), consistent with the elevated levels of AP1 pro-
teins in UM cells (Figure 6B). These results suggest a possible
mechanism involving AP1 upregulation to enhance YAP/Tead
downstream transcriptional output.
Dual Inhibition of TEAD and MEK in Human UM Cells
To further explore the interplay between YAP/Tead and Ras/
MAPK in human UM cells, we treated 92-1 cells with a MEK in-
hibitor, PD0325901. PD0325901 inhibited ERK phosphorylation
in a dose-dependent manner in 92-1 cells (Figure 6D). The
expression of several AP1 genes, including c-Jun, Fos, FosL1,
and FosL2, was downregulated after PD0325901 treatment,
and their transcription was synergistically suppressed when
both MEK and TEAD activation was inhibited (Figure 6E). Overall
AP1 transcriptional activity in 92-1 cells was also significantly
decreased by dual inhibition of TEAD and MEK, measured by
the AP1-dependent luciferase reporter (AP1-Luc) assay (Fig-
ure 6F). Consistent with the notion of transcriptional cooperation
between the two pathways, we found that ectopic expression of
DN-TEAD4 and treatment of PD0325901 synergized to inhibit the
transcription of CTGF, CYR61, and ANKRD1 (Figure 6G), as well
as the YAP/TAZ target genes involved in regulation of cell prolif-
eration and apoptosis, Myc, Cyclin D1, and BirC5 (Figures 6G
and 7A).
Further analysis showed PD0325901 treatment at 10 nM, a
concentration that effectively blocked ERK phosphorylation in
92-1 UM cells (Figure 6D), had largely no effect on cell viability,
measured by the MTT assay (Figure 7B). MEK inhibition by
PD0325901 also did not significantly induce apoptosis in
92-1 UM cells, detected by western blot analysis of cleaved pol-
y(ADP-ribose) polymerase (PARP) (Figure 7A). These data sug-
gest that MEK inhibition alone has little or no effect on UM cells,
consistent with previous reports on the failure of MAPK inhibition
in clinical trials (Carvajal et al., 2014; Komatsubara et al., 2016).
However, we found that blocking MEK activity could sensitize
the inhibitory activity of DN-TEAD4 in UM cells. YAP/TEAD inhi-
bition by DN-TEAD4 in 92-1 cells was sufficient to decrease cell
viability, block cell migration, and inhibit their ability to undergo
anchorage-independent growth (Figures 7B–7F), measured by
transwell migration and soft agar colony formation assays.
Importantly, we also observed the synergy of dual inhibition of
TEAD and MEK in these assays (Figures 7A–7F), suggesting
the potential therapeutic benefit of targeting both YAP/TEAD
and Ras/MAPK pathways in human UM cells.
DISCUSSION
In this study, we developed an AAV-based ocular injection
method to deliver melanocyte-specific Cre directly into mouse
uveal tract to facilitate genetic mouse modeling of UM. Our
ocular-specific Cre delivery method provides clear advantages
over the general melanocyte Cre lines, such as Mitf-Cre or Tyr-
CreER, that have been used to model UM (Huang et al., 2015;
Moore et al., 2018). These Cre lines also drive Cre expression
in melanocytes or melanocyte-like cells in tissues outside the
uveal tract, including skin, CNS, lung, and inner ear, which often
leads to early lethality and additional phenotypes in other organs
that complicate phenotypic analysis of UM (Huang et al., 2015;
Moore et al., 2018). In contrast, our AAV-based uveal tract Cre
delivery allows manipulation of oncogene or tumor suppressor
activity specifically in uveal melanocytes. Using this robust plat-
form, we demonstrated the ability of Lats1/2 deletion or YAP
activation to initiate UM and uncovered its cooperation with
Kras to promote UM progression. Our data also revealed that
Kras activation alone is not sufficient to induce UM, consistent
with a recent report showing the inability of Braf activation to
initiate UM (Moore et al., 2018). These data highlight the intrinsic
difference of oncogenic transformation between the melano-
cytes in uveal tract and skin, given the fact that Braf/MAPK acti-
vation is the dominant oncogenic driver in cutaneous mela-
nomas. Because of the inability of Kras activation alone to
induce UM, it also suggests that Ras/MAPK may not play a sig-
nificant role in UM initiation. The mechanism underlying GNAQ/
11-driven oncogenic transformation of uveal melanocytes is
likely complex. Our data focus on the role of dysregulated Hippo
signaling via Lats1/2 inactivation or YAP activation in UM
(G) Immunoblot analysis of pERK1/2, total ERK1/2, YAP, TAZ, and GAPDH in UMs derived from AAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl and AAV5-Trp2-
GFPCre;Lats1fl/fl;Lats2fl/fl;LSL-KrasG12D mice.
(H) qPCR analysis of transcription levels of YAP, TAZ, Tead1, Tead4, CTGF, Cyr61, ANKRD1, Myc, and Cyclin D1 in UMs derived from AAV5-Trp2-GFPCre;
Lats1fl/fl;Lats2fl/fl and AAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl;LSL-KrasG12D mice.
Data are mean ± SD. *p% 0.05, **p% 0.01. See also Figure S4.
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Figure 6. AP1 Transcriptional Upregulation in UM Cells with YAP/TAZ and Kras Activation
(A) qPCR analysis of mRNA levels of c-Jun, JunB, JunD, Fos, FosL1, and FosL2 in UMs derived from AAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl (LatsDKO) and AAV5-
Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl;LSL-KrasG12D (LatsDKO/KrasG12D) mice.
(B) Immunoblot analysis of c-Jun, JunB, FosL1, Myc, and GAPDH in UMs developed in AAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl and AAV5-Trp2-GFPCre;Lats1fl/fl;
Lats2fl/fl;LSL-KrasG12D mice.
(C) ChIP-qPCR analysis shows significantly more enrichment of c-Jun at the promoter regions of the CTGF, Cyr61, ANKRD1,Myc, and CyclinD1 genes in UMs
from AAV5-Trp2-GFPCre;Lats1fl/fl;Lats2fl/fl;LSL-KrasG12D mice.
(D) Immunoblot analysis of pERK1/2 and total ERK1/2 levels in 92-1 cells treated with PD0325901 at different concentrations.
(E) qPCR analysis of mRNA levels of c-Jun, JunB, JunD, Fos, FosL1, and FosL2 in 92-1 UM cells with or without DN-TEAD4 expression or PD0325901 (PD)
treatment at 10 nM.
(F) Relative AP1-luciferase reporter (AP1-Luc) activity in 92-1 UM cells with or without DN-TEAD4 expression or PD0325901 (PD) treatment.
(G) qPCR analysis of mRNA levels of CTGF, CYR61, ANKRD1,Myc, Cyclin D1, and Birc5 in 92-1 UM cells with or without DN-TEAD4 expression or PD0325901
(PD) treatment.
Data are mean ± SD. *p% 0.05, **p% 0.01.
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genesis; however, additional studies are needed to explore the
possible interactions between Hippo/Yap and other oncogenic
pathways downstream of GNAQ/11, such as PLCb and PKC
(Chen et al., 2014, 2017).
Our studies here reveal the cooperation between YAP/TAZ and
Ras/MAPK during UM progression and suggest a possible mech-
anism of transcriptional reinforcement between the two pathways
in UM cells. First, we showed that YAP directs a subset of its
downstream transcriptional program to promote the expression
of Prkcd, Rras2, Nras, and RasGRP1, directly or indirectly, in
UM cells (Figure 7G). It likely forms a part of the molecular basis
of YAP/TAZ promotion of Ras/MAPK signaling in cancer cells,
and our data agree with a recent report of YAP regulation of Ras
gene transcription in NF2-mutated thyroid cancers (Garcia-Re-
ndueles et al., 2015). In addition, our results suggest that YAP/
Tead-related transcriptional output is further augmented in UM
cells with both YAP/TAZ and Ras/MAPK activation, and likely in-
volves AP1 upregulation.We recently showedAP1-Tead co-oper-
ation as a critical mechanistic node to coordinate downstream
transcription in cancer cells (Liu et al., 2016). Our results here
linked AP1 to Tead-mediated transcription in UM. Ras activation
is associated with YAP regulation in different tumor contexts (Ka-
poor et al., 2014; Shao et al., 2014; Garcia-Rendueles et al., 2015).
Two prior studies on acquired resistance to Kras suppression in
colon, lung, and pancreatic cancers show that YAP can rescue
cell viability and sustain tumor growth in the setting of Kras sup-
pression (Kapoor et al., 2014; Shao et al., 2014). However,
different mechanismswere proposed, and one of the studies sug-
gests that Kras and YAP converge on one of the AP1 factors, Fos,
in a Tead-independent manner (Shao et al., 2014). Our data pro-
vide an alternative model of Ras-YAP interaction in UM cells, in
which upregulation of AP1 factors leads to their further engage-
ment on the Tead-occupied enhancer or promoter regions, there-
fore amplifying YAP/Tead-mediated downstream oncogenic
output. It is intriguing to test whether such Ras-AP1-YAP/Tead
regulatory axis functions in other tumors associated with Hippo
dysregulation and Ras activation.
Our data from genetically modified mouse models and human
UMcells highlight the potential of YAP/Tead as the valid therapeu-
tic targets for UM. The cooperation of YAP/TAZandRas/MAPKon
Figure 7. Combination Inhibition of YAP/TEAD and MAPK in Human UM Cells
(A) Immunoblot analysis of Myc and cleaved PARP (cPARP) in 92-1 UM cells with or without DN-TEAD4 expression or PD0325901 treatment.
(B–F) Cell viability (B), migration (C), and soft agar colony formation (E) in 92-1 UM cells with or without DN-TEAD4 expression or PD0325901 treatment. Cell
viability was measured by MTT assay, and migration was measured by transwell migration assay. Quantitation of cell migration and soft agar colony formation
assays was shown in (D) and (F). Data are mean ± SD. *p% 0.05, **p% 0.01.
(G) A schematic model showing distinct roles of YAP/TAZ and Ras/MAPK in Gq/11-driven UM initiation and progression. YAP/TAZ activation induces UM
initiation, and the cooperation of YAP/TAZ and Ras/MAPK via downstream transcriptional programs further promotes UM progression.
Cell Reports 29, 3200–3211, December 3, 2019 3209
UMprogression (Figure 7G) likely has important therapeutic impli-
cation as well. Clinical trials with MEK inhibitors targeting Ras
signaling in UM failed in phase 3 trials (Carvajal et al., 2014; Ko-
matsubara et al., 2016), and combination targeting of additional
pathways including PKC has already been proposed (Chen
et al., 2014, 2017). Our results argue that dual inhibition of both
YAP/Tead and Ras/MAPK may have greater therapeutic benefit
in UM. In light of our data on the potential involvement of AP1 fac-
tors in YAP-Ras interaction, targeting AP1will also be an intriguing
strategy for UM treatment, which is consistent with a previous
report suggesting AP1’s role in UM cells (Vaque´ et al., 2013).
Clearly further functional and pre-clinical studies on the interplay
among these pathways in UM are warranted.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-YAP Cell Signaling Cat# 14074; RRID:AB_2650491
Rabbit anti-YAP/TAZ Cell Signaling Cat# 8418; RRID:AB_10950494
Rabbit anti-Phospho-YAP (Ser127) Cell Signaling Cat# 13008; RRID:AB_2650553
Mouse anti-TAZ BD PharMingen Cat# 560235; RRID:AB_1645338
Rabbit anti-Lats2 Cell Signaling Cat# 5888; RRID:AB_10835233
Rabbit anti-Ki67 Abcam Cat# ab15580; RRID:AB_443209
Rabbit anti-phospho Histone H3 Cell Signaling Cat# 9701; RRID:AB_331535
Rabbit anti-ERK1/2 Cell Signaling Cat# 4695; RRID:AB_390779
Rabbit anti-phospho-ERK1/2 Cell Signaling Cat# 4370; RRID:AB_2315112
Rabbit anti-MEK1/2 Cell Signaling Cat# 9126; RRID:AB_331778
Rabbit anti-phospho-MEK1/2 Cell Signaling Cat# 9154; RRID:AB_2138017
Rabbit anti-cJun Cell Signaling Cat# 9165; RRID:AB_2130165
Rabbit anti-JunB Bethyl Cat# A302-704A; RRID:AB_10749029
Rabbit anti-FosL1 SCBT Cat# sc183; RRID:AB_2106928
Rabbit anti-Myc Cell Signaling Cat# 5605; RRID:AB_1903938
Rabbit anti-Myc tag Cell Signaling Cat# 2278; RRID:AB_490778
Rabbit anti-cleaved PARP (Asp214) Cell Signaling Cat# 9541; RRID:AB_331426
Mouse anti-Melanoma cocktail (Melan A/Mart-1) Abcam Cat# ab732; RRID:AB_305844
Mouse anti-TEAD4 SCBT Cat# sc-101184; RRID:AB_2203086
Rabbit anti-GAPDH Bethyl Cat# A300-641A;RRID:AB_513619
Normal Rabbit IgG Cell Signaling Cat# 272AB_3907799; RRID:AB_1031062
Normal Mouse IgG SCBT Cat# sc-2025; RRID:AB_737182
HRP conjugated goat anti-rabbit Promega Cat# W4011; RRID:AB_430833
HRP conjugated goat anti-mouse Promega Cat# W4021; RRID:AB_430834
Anti-Rabbit HRP Cell Signaling Cat# 7074S; RRID:AB_2099233
Anti-Mouse HRP Cell Signaling Cat# 7076S; RRID:AB_330924
Mouse TrueBlot ULTRA: Anti-Mouse Ig HRP Rockland Cat# 18-8817-33; RRID:AB_2610851
Rabbit TrueBlot ULTRA: Anti-Mouse Ig HRP Rockland Cat# 18-8816-33; RRID:AB_2610848
Alexa Fluor 568, goat anti-rabbit Invitrogen Cat# A-11011; RRID:AB_143157
Alexa Fluor 633, goat anti-rabbit Invitrogen Cat# A-21070; RRID:AB_2535731
Alexa Fluor 568, goat anti-mouse Invitrogen Cat# A-11004; RRID:AB_2534072
Alexa Fluor 633, goat anti-mouse Invitrogen Cat# A-21050; RRID:AB_141431
Bacterial and Virus Strains
AAV5-CMV-Cre UMass Vector Core N/A
AAV5-TRP2-GFPCre UMass Vector Core N/A
Chemicals, Peptides, and Recombinant Proteins
Protease inhibitor Promega Cat# G653A
Phosphatase inhibitor cocktail 2 Sigma Cat# P5726
PD0325901 Selleckchem Cat# S1036
Critical Commercial Assays
Vectastain Elite ABC kit Vector Lab Cat# 1725124
Dual-Luciferase Reporter Assay System Promega Cat# PK-6011
ChIP-IT Express ChIP Kit Active Motif Cat# E1910
Trizol reagent Invitrogen Cat# BP-111R
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Junhao
Mao (junhao.mao@umassmed.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All animals use protocols were reviewed and approved by The University of Massachusetts Medical School Institutional Animal
Care and Use Committee. R26-YAP5SA (Cotton et al., 2017), Lats1flox and Lats2flox (Yi et al., 2016) mice were described previously.
LSL-KrasG12D (Jackson et al., 2001) and R26mT/mG (Muzumdar et al., 2007) mice were obtained from the Jackson laboratory. Yapflox
(Xin et al., 2011) and Tazflox (Xin et al., 2013) mice were kindly provided by Dr. EN Olson. The mice used in this study were maintained
in a genetic background with SwissWebster (CFW) as the major component, and both male and female mice between 2-4 months of
age were used for AAV injection.
METHOD DETAILS
AAV Injection in Mouse Uveal Tract
AAV5-CMV-Cre vector was obtained fromUMass Vector Core. For AAV5-TRP2-GFPCre, the 1.7Kb TRP2 promoter region (Zhao and
Overbeek, 1999) was PCR amplified from mouse genomic DNA, and cloned into the pssAAV packaging plasmid together with a
GFP-Cre fragment (a gift from Fred Gage, Addgene # 49056) to generate the pssAAV-TRP2-GFPCre construct. AAV5-TRP2-GFPCre
vector was then produced by UMass Vector Core. For AAV uveal tract injection, recombinant AAV injections into the uveal track were
performed as previously described (Venkatesh et al., 2013) with the following modification. In brief, mice were anesthetized with a
mixture of ketamine/xylazine (100mg/kg and 10mg/kg). Eyes were cleaned with betadine followed by water and 70% ethanol. There-
after 0.5 ml of virus was injected directly into the choroid by inserting a beveled glass needle through the sclera. In order to not push
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
RNaseq data of Lats1/2 KO mouse UM This paper GEO: GSE115181
Experimental Models: Cell Lines
Human HEK293 cell line ATCC Cat# CRL-1573
Human 92-1 Uveal melanoma cell line Sigma Cat# 13012458-1VL
Experimental Models: Organisms/Strains
Mouse: Lats1flox Yi et al., 2016 JAX# 024941
Mouse: Lats2flox Yi et al., 2016 JAX# 025428
Mouse: YAPflox Xin et al., 2011 N/A
Mouse: TAZflox Xin et al., 2013 N/A
Mouse: R26-YAP5SA Cotton et al., 2017 N/A
Mouse: R26mT/mG Muzumdar et al., 2007 JAX# 007676
Mouse: LSL-KrasG12D Jackson et al., 2001 JAX# 008179
Oligonucleotides
Primers for qPCR This paper Table S2
Primers for ChIP-qPCR This paper Table S2
Recombinant DNA
AAV5-TRP2-GFPCre This paper N/A
pGIPZ-DN-TEAD4 This paper N/A
pGIPZ-FLAG-nls-YAP5SA Cotton et al., 2017 N/A
pBABE-TAZ4SA Gift of Dr. Kun-liang Guan, UCSD N/A
AAV-GFP-Cre Addgene Addgene #49056
8XGTIIC-Luc (TBS-Luc) Addgene Addgene #34615
AP1-Luc Addgene Addgene #40432
Software and Algorithms
Fiji (ImageJ) Schindelin et al., 2012 Fiji (ImageJ)
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the needle across the sclera into the sub retinal space the needle was inserted at a flat angle. Successful targeting was visualized by
bulging of the scleral/chorodial tissue, which does not occur if the needle crosses into the sub retinal space. Injections were per-
formed using an air pressured injection pump (FemtoJet: Eppendorf). After removal of the needle corneal lubricant was applied
and animals were kept at 37C until fully recovered. All mouse experiments were conducted according to the University of Massa-
chusetts Medical School IACUC guidelines.
Tissue Collection and Histology
Following euthanasia, tumors or eyes were dissected and fixed in 10% Neutral Buffered Formalin (NBF) at 4C overnight. For
paraffin sections, tissue was dehydrated, embedded in paraffin, and sectioned at 6 mm. For frozen sections, tissue was dehydrated
in 30% sucrose overnight at 4C, embedded in OCT, and sectioned at 12 mm. Paraffin sections were stained using standard hema-
toxylin & eosin reagents.
Immunohistochemistry, Immunofluorescence and b-Galactosidase Staining
For immunohistochemistry (IHC), sections were deparaffinized and rehydrated before undergoing heat-induced antigen retrieval in
10mM sodium citrate buffer (pH 6.0) for 30minutes. Slides were blocked for endogenous peroxidase for 20minutes, then blocked for
1 hour in 5% BSA, 1% goat serum, 0.1% Tween-20 buffer in PBS, and incubated overnight at 4C in primary antibody diluted in
blocking buffer or SignalStain Antibody Diluent (Cell Signaling). Slides were incubated in biotinylated secondary antibodies for
1 hour at room temperature and signal was detected using the Vectastain Elite ABC kit (Vector Laboratories). Hematoxylin was
used for counterstaining in IHC. For b-galactosidase staining, frozen sections were cut at 12mM intervals and subjected to standard
b-galactosidase staining. For immunofluorescence (IF) cells or tissue sections were fixed by 4% paraformaldehyde for 5 minutes,
blocked for 1 hour and incubated overnight at 4C in primary antibody diluted in blocking buffer. Slides were then incubated for
1 hour at room temperature in Alexa Fluor-conjugated secondary antibodies (Invitrogen) in blocking buffer and mounted using
mounting media with DAPI (EMS). All primary and secondary antibodies used for IHC/IF were described in the KEY RESOURCES
TABLE.
Immunoblotting Analysis
Mouse tumor and control eye tissues were dissected and lysed, and the lysate was then incubated with indicated antibody overnight.
The immunoprecipitates were washed five times with RIPA buffer, before subjecting to immunoblot analysis. All primary and second-
ary antibodies used for IHC/IF were described in the KEY RESOURCES TABLE.
RNaseq Analysis
For mouse UM, tissue was homogenized in the Trizol reagent (Thermo Fisher) and RNA was extracted according to manufacturer’s
instructions. For control tissue, eyes were enuclated and cornea, lens, retina, optic nerve and muscle attachments were removed to
obtain tissue largely containing the uveal tract, RPE, and sclera. The integrity of isolated RNAwas analyzed using Bioanalyzer (Agilent
Technologies). RNA-seq libraries were made with Illumina Truseq RNA Sample Prep protocol by UMass Deep Sequencing Core and
sequenced on Illumina HiSeq2000. All libraries have around 20-30 million reads sequenced. Quality assessment of the raw reads
(single end 75bp) was performed using fastqc (FastQC: a quality control tool for high throughput sequence data. Available online
at: (http://www.bioinformatics.babraham.ac.uk/projects/fastqc), followed by alignment to the reference mouse genome (mm10) us-
ing tophat (Kim et al., 2013). Cufflinks (Trapnell et al., 2012) was used for identifying differentially expressed genes between wild-type
and knock out group. Genes with q-value < 0.05 and fold change greater than 1.5 were considered as significantly differential
expressed genes. In addition, Pathway and GO enrichment analysis was performed using ChIPpeakAnno package (Zhu, 2013;
Zhu et al., 2010). The RNaseq data were deposited into the GEO repository and the accession number is GSE115181.
Chromatin Immunoprecipitation-qPCR Analysis
ChIP assays were performed using ChIP-IT Express Chromatin Immunoprecipitation Kit according to the manufacturer’s instruc-
tions (ActiveMotif, Cat # 53008). Briefly, freshly dissected tissues were fixedwith 1% formaldehyde, washedwith cold PBS and lysed
in lysis buffer. After sonication, protein-DNA complexes were incubated with Tead4 (SCBT) or c-Jun (Cell Signaling) antibodies-
coupled protein G beads at 4C overnight. After elution and reverse cross-link, DNA was purified for subsequent PCR analysis.
The antibodies used for ChIP were described in the KEY RESOURCES TABLE. The primers used for real-time PCR of the promoter
regions were described in Table S2.
Quantitative Real-Time PCR
Total RNA of animal tissues and human UM cells was isolated using Trizol reagent (Thermo Fisher). cDNA was prepared using Su-
perscript II Reverse Transcriptase (Thermo Fisher), and the amount of transcripts were quantified using SybrMastermix (KapaBiosci-
ence), with the respective oligonucleotides (Table S2) in Applied Biosystems 7300 RT-PCR systems. The number of copies of each
gene was normalized to the housekeeping gene GAPDH. All qPCR experiments were conducted in biological triplicates, error bars
represent mean ± standard deviation, and Student’s t test was used to generate p values (* = p value% 0.05; ** = p value% 0.01).
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Cell Culture, Treatment and Lentiviral Infection
92-1 cells (human uveal melanoma cells, female) were cultured in RPMI supplemented with 10% FBS and treated with MEK inhibitor
PD0325901 (Selleckchem) at 10nM for various analyses. To generate DN-TEAD4 lentiviral expression vector, the cDNA fragments
encoding human TEAD4 were PCR cloned into a pGIPZ-based lentiviral vector. For lentiviral infection, pGIPZ constructs were trans-
fected along with the packing plasmids into growing HEK293T cells (human embryonic kidney cells, female). Viral supernatants were
collected 48 hours after transfection, and target cells were infected in the presence of polybrene and underwent selection with
puromycin for 3-4 days before subsequent analyses.
Luciferase Reporter Analysis
Tead-Luc (8xGTIIC-luciferase) was a gift from Stefano Piccolo (Addgene # 34615), and AP1-Luc (3xAP-1 in pGL3-basic) was a gift
fromAlexander Dent (Addgene # 40342). For 8xGTIIC-Luc reporter assay, HEK293T cells were transfected using Lipofectamine 2000
(Invitrogen) with 8xGTIIC-Luc reporter construct together with the expression plasmids of Renila-luciferase, DN-TEAD4, YAP-5SA or
TAZ-4SA (a gift fromDr. Kun-liangGuan, UCSD) for 48 hours. For AP1-Luc reporter assay, 92-1 cells were transfected using Lipofect-
amine 2000 (Invitrogen) with AP1-Luc reporter construct together with the expression plasmids of Renila-luciferase and DN-TEAD4
with or without 10nM PD0325901 treatment for 48 hours. Luciferase activity was measured as using the Dual-Luciferase
reporter assay system (Promega, Cat # E1910) according to the manufacturer’s protocol. All luciferase reporter experiments were
conducted in biological triplicates, error bars represent mean ± standard deviation, and Student’s t test was used to generate
p values. (* = p value% 0.05; ** = p value% 0.01).
MTT, Soft Agar Colony Formation, and Cell Migration Assays
MTT assay was performed using CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega, Cat # G4000). For anchorage-in-
dependent soft-agar colony formation assay, 92-1 cells were seeded at a density of 6000 cells/well in a 6-well plate of 0.3% agarose
in RPMI media containing 10% FBS. Colonies from 12 fields of view were counted 14 days later. Assays were conducted in tripli-
cates, and standard deviation was used to calculate error bars. For transwell migration assays, 5X104 cells were plated in the top
chamber with the non-coated membrane (24-well insert; pore size, 8 mm; BD Biosciences) and in medium without serum, and me-
dium supplemented with serumwas used as a chemoattractant in the lower chamber. The cells were incubated for 24h and cells that
did not migrate or invade through the pores were removed by a cotton swab. Cells on the lower surface of the membrane were
stained with the Diff-Quick Staining Set (Dade) and counted.
QUANTIFICATION AND STATISTICAL ANALYSIS
No statistical method was used to predetermine sample size. The experiments were not randomized. For biochemical experiments
we performed the experiments at least three independent times. Experiments for which we showed representative images were per-
formed successfully at least 3 independent times. No samples or animal were excluded from the analysis. The investigators were not
blinded to allocation during experiments and outcome assessment. Student’s t test was used to generate p values (* = p value%
0.05; ** = p value% 0.01). The variance was similar between groups that we compared.
DATA AND CODE AVAILABILITY
The accession number for the RNA-Seq data of Lats1/2 deleted mouse uveal melanoma is GEO: GSE115181.
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